Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Other Non-Current Liabilities (2016 - 2025)

Sanofi (SNY) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $7.8 billion as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 9.81% to $7.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 billion through Dec 2025, down 9.81% year-over-year, with the annual reading at $7.6 billion for FY2025, 13.57% down from the prior year.
  • Other Non-Current Liabilities hit $7.8 billion in Q4 2025 for Sanofi, down from $8.7 billion in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $8.7 billion in Q4 2024 to a low of $1.3 billion in Q4 2022.
  • Historically, Other Non-Current Liabilities has averaged $5.4 billion across 5 years, with a median of $7.8 billion in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: fell 28.44% in 2021 and later surged 550.2% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $1.3 billion in 2021, then dropped by 1.64% to $1.3 billion in 2022, then soared by 550.2% to $8.2 billion in 2023, then grew by 5.77% to $8.7 billion in 2024, then decreased by 9.81% to $7.8 billion in 2025.
  • Business Quant data shows Other Non-Current Liabilities for SNY at $7.8 billion in Q4 2025, $8.7 billion in Q4 2024, and $8.2 billion in Q4 2023.